Compare TSQ & SLGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TSQ | SLGL |
|---|---|---|
| Founded | 1996 | 1997 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Broadcasting | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 110.8M | 117.8M |
| IPO Year | 2000 | 2018 |
| Metric | TSQ | SLGL |
|---|---|---|
| Price | $5.06 | $44.00 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $12.50 | ★ $50.00 |
| AVG Volume (30 Days) | ★ 72.0K | 16.0K |
| Earning Date | 11-10-2025 | 11-20-2025 |
| Dividend Yield | ★ 15.53% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.14 | N/A |
| Revenue | ★ $438,695,000.00 | $18,970,000.00 |
| Revenue This Year | N/A | $121.82 |
| Revenue Next Year | $1.59 | N/A |
| P/E Ratio | $4.51 | ★ N/A |
| Revenue Growth | N/A | ★ 62.04 |
| 52 Week Low | $4.30 | $4.02 |
| 52 Week High | $10.23 | $52.26 |
| Indicator | TSQ | SLGL |
|---|---|---|
| Relative Strength Index (RSI) | 45.69 | 53.60 |
| Support Level | $5.13 | $38.91 |
| Resistance Level | $5.34 | $43.12 |
| Average True Range (ATR) | 0.25 | 3.32 |
| MACD | 0.04 | -0.09 |
| Stochastic Oscillator | 44.16 | 51.15 |
Townsquare Media Inc is a radio, digital media, entertainment, and digital marketing solutions company principally focused on being the premier local advertising and marketing solutions platform in small and mid-sized markets across the United States. It has three segments which are Subscription Digital Marketing Solutions, Digital Advertising, and Broadcast Advertising. It earns the majority of the revenue from the Broadcasting Advertising segment, which includes its local, regional, and national advertising products and solutions delivered via terrestrial radio broadcast. Its portfolio includes local media brands such as WYRK.com, WJON.com, and NJ101.5.com, and premier national music brands such as XXLmag.com, TasteofCountry.com, UltimateClassicRock.com, and Loudwire.com.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted.